You are viewing the site in preview mode

Skip to main content

Table 3 Summary of ORR and CRR comparisons between the TRANSCEND and ZUMA-1 studies

From: Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma

  ZUMA-1 (axi-cel) TRANSCEND (liso-cel) Liso-cel versus axi-cel
N (%) Response rate, % N/ESS Response rate, % OR (95% CI) P
ORR
 Naïve comparison 101 74.3 256 72.7 0.92 (0.54–1.55) 0.753
 Initial analysis    42.1 80.1 1.40 (0.56–3.49) 0.476
 Sensitivity analysis 1    150.3 71.2 0.85 (0.48–1.52) 0.591
 Sensitivity analysis 2    98.9 70.9 0.84 (0.45–1.58) 0.596
CRR
 Naïve comparison 101 54.5 256 53.1 0.95 (0.60–1.50) 0.815
 Initial analysis    39.6 59.2 1.21 (0.56–2.64) 0.630
 Sensitivity analysis 1    169.1 48.2 0.78 (0.47–1.27) 0.318
 Sensitivity analysis 2    98.9 49.5 0.82 (0.47–1.43) 0.483
  1. Axi-cel, axicabtagene ciloleucel; CI, confidence interval; CRR, complete response rate; ESS, effective sample size; liso-cel, lisocabtagene maraleucel; N, sample size; OR, odds ratio; ORR, objective response rate
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us